Role of bacterial infections in allograft rejection

References

• Fehr T, Sykes M. Tolerance induction in clinical transplantation. Transpl. Immunol.13(2), 117–130 (2004).
   PubMed Web of Science ®Google Scholar
• LaRosa DF, Rahman AH, Turka LA. The innate immune system in allograft rejection and tolerance. J. Immunol.178(12), 7503–7509 (2007).
   PubMed Web of Science ®Google Scholar
• McLaughlin K, Wu C, Fick G et al. Cytomegalovirus seromismatching increases the risk of acute renal allograft rejection. Transplantation74(6), 813–816 (2002).
   PubMed Web of Science ®Google Scholar
• Reinke P, Fietze E, Ode-Hakim S et al. Late-acute renal allograft rejection and symptomless cytomegalovirus infection. Lancet344(8939–8940), 1737–1738 (1994).
   PubMed Web of Science ®Google Scholar
• Sageda S, Nordal KP, Hartmann A et al. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am. J. Transplant.2(9), 850–856 (2002).
   PubMed Web of Science ®Google Scholar
• Vilchez RA, Dauber J, McCurry K, Iacono A, Kusne S. Parainfluenza virus infection in adult lung transplant recipients: an emergent clinical syndrome with implications on allograft function. Am. J. Transplant.3(2), 116–120 (2003).
   PubMed Web of Science ®Google Scholar
• Cainelli F, Vento S. Infections and solid organ transplant rejection: a cause-and-effect relationship? Lancet Infect. Dis.2(9), 539–549 (2002).
   PubMed Web of Science ®Google Scholar
• Lopez C, Simmons RL, Mauer SM et al. Association of renal allograft rejection with virus infections. Am. J. Med.56(3), 280–289 (1974).
   PubMed Web of Science ®Google Scholar
• Hale DA. Basic transplantation immunology. Surg. Clin. North Am.86(5), 1103–1125 (2006).
   PubMed Web of Science ®Google Scholar
• Bruno DA, Dhanireddy KK, Kirk AD. Challenges in therapeutic strategies for transplantation: where now from here? Transpl. Immunol.15(2), 149–155 (2005).
   PubMed Web of Science ®Google Scholar
• Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB. Strategies to improve long-term outcomes after renal transplantation. N. Engl. J. Med.346(8), 580–590 (2002).
   PubMed Web of Science ®Google Scholar
• Patel R, Paya CV. Infections in solid-organ transplant recipients. Clin. Microbiol. Rev.10(1), 86–124 (1997).
   PubMed Web of Science ®Google Scholar
• Rubin RH. Temporal aspects of transplant infectious disease. Transpl. Infect. Dis.5(2), 63–64 (2003).
   PubMedGoogle Scholar
• Fishman JA, Rubin RH. Infection in organ-transplant recipients. N. Engl. J. Med.338(24), 1741–1751 (1998).
   PubMed Web of Science ®Google Scholar
• Singh N. Infections in solid organ transplant recipients. Curr. Opin. Infect. Dis.13(4), 343–347 (2000).
   PubMed Web of Science ®Google Scholar
• Sharples LD, McNeil K, Stewart S, Wallwork J. Risk factors for bronchiolitis obliterans: a systematic review of recent publications. J. Heart Lung Transplant.21(2), 271–281 (2002).
   PubMed Web of Science ®Google Scholar
• El-Gamel A, Sim E, Hasleton P et al. Transforming growth factor b (TGF-b) and obliterative bronchiolitis following pulmonary transplantation. J. Heart Lung Transplant.18(9), 828–837 (1999).
   PubMed Web of Science ®Google Scholar
• Wilkes DS, Egan TM, Reynolds HY. Lung transplantation: opportunities for research and clinical advancement. Am. J. Respir. Crit. Care Med.172(8), 944–955 (2005).
   PubMed Web of Science ®Google Scholar
• Estenne M, Maurer JR, Boehler A et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J. Heart Lung Transplant.21(3), 297–310 (2002).
   PubMed Web of Science ®Google Scholar
• Norgaard MA, Andersen CB, Pettersson G. Does bronchial artery revascularization influence results concerning bronchiolitis obliterans syndrome and/or obliterative bronchiolitis after lung transplantation? Eur. J. Cardiothorac. Surg.14(3), 311–318 (1998).
   PubMed Web of Science ®Google Scholar
• Girgis RE, Tu I, Berry GJ et al. Risk factors for the development of obliterative bronchiolitis after lung transplantation. J. Heart Lung Transplant.15(12), 1200–1208 (1996).
   PubMed Web of Science ®Google Scholar
• Heng D, Sharples LD, McNeil K et al. Bronchiolitis obliterans syndrome: incidence, natural history, prognosis, and risk factors. J. Heart Lung Transplant.17(12), 1255–1263 (1998).
   PubMed Web of Science ®Google Scholar
• Bando K, Paradis IL, Similo S et al. Obliterative bronchiolitis after lung and heart–lung transplantation. An analysis of risk factors and management. J. Thorac. Cardiovasc. Surg.110(1), 4–13 (1995).
   PubMed Web of Science ®Google Scholar
• Glanville AR, Gencay M, Tamm M et al. Chlamydia pneumoniae infection after lung transplantation. J. Heart Lung Transplant.24(2), 131–136 (2005).
   PubMed Web of Science ®Google Scholar
• Husain S, Kahane S, Friedman MG et al.Simkania negevensis in bronchoalveolar lavage of lung transplant recipients: a possible association with acute rejection. Transplantation83(2), 138–143 (2007).
   PubMed Web of Science ®Google Scholar
• Wiebe K, Fraund S, Steinmuller C, Steinhoff G. Rat cytomegalovirus and Listeria monocytogenes infection enhance chronic rejection after allogenic rat lung transplantation. Transpl. Int.18(10), 1166–1174 (2005).
   PubMed Web of Science ®Google Scholar
• Reyes J, Bueno J, Kocoshis S et al. Current status of intestinal transplantation in children. J. Pediatr. Surg.33(2), 243–254 (1998).
   PubMed Web of Science ®Google Scholar
• Sigurdsson L, Reyes J, Kocoshis SA et al. Bacteremia after intestinal transplantation in children correlates temporally with rejection or gastrointestinal lymphoproliferative disease. Transplantation70(2), 302–305 (2000).
   PubMed Web of Science ®Google Scholar
• Berg RD. Promotion of the translocation of enteric bacteria from the gastrointestinal tracts of mice by oral treatment with penicillin, clindamycin, or metronidazole. Infect. Immun.33(3), 854–861 (1981).
   PubMed Web of Science ®Google Scholar
• Deitch EA, Maejima K, Berg R. Effect of oral antibiotics and bacterial overgrowth on the translocation of the GI tract microflora in burned rats. J. Trauma25(5), 385–392 (1985).
   PubMedGoogle Scholar
• Wells CL. Colonization and translocation of intestinal bacterial flora. Transplant. Proc.28(5), 2653–2656 (1996).
   PubMed Web of Science ®Google Scholar
• Cicalese L, Sileri P, Green M et al. Bacterial translocation in clinical intestinal transplantation. Transplantation71(10), 1414–1417 (2001).
   PubMed Web of Science ®Google Scholar
• Rubin RH. Infectious disease complications of renal transplantation. Kidney Int.44(1), 221–236 (1993).
   PubMed Web of Science ®Google Scholar
• Nampoory MR, Johny KV, Costandy JN et al. Infection related renal impairment: a major cause of acute allograft dysfunction. Exp. Clin. Transplant.1(1), 60–64 (2003).
   PubMedGoogle Scholar
• Giral M, Pascuariello G, Karam G et al. Acute graft pyelonephritis and long-term kidney allograft outcome. Kidney Int.61(5), 1880–1886 (2002).
   PubMed Web of Science ®Google Scholar
• Kamath NS, John GT, Neelakantan N, Kirubakaran MG, Jacob CK. Acute graft pyelonephritis following renal transplantation. Transpl. Infect. Dis.8(3), 140–147 (2006).
   PubMed Web of Science ®Google Scholar
• Audard V, Amor M, Desvaux D et al. Acute graft pyelonephritis: a potential cause of acute rejection in renal transplant. Transplantation80(8), 1128–1130 (2005).
   PubMed Web of Science ®Google Scholar
• Ozdemir BH, Sar A, Uyar P et al. Posttransplant tubulointerstitial nephritis: clinicopathological correlation. Transplant. Proc.38(2), 466–469 (2006).
   PubMed Web of Science ®Google Scholar
• Chuang P, Parikh CR, Langone A. Urinary tract infections after renal transplantation: a retrospective review at two US transplant centers. Clin. Transplant.19(2), 230–235 (2005).
   PubMed Web of Science ®Google Scholar
• Memikoglu KO, Keven K, Sengul S et al. Urinary tract infections following renal transplantation: a single-center experience. Transplant. Proc.39(10), 3131–3134 (2007).
   PubMed Web of Science ®Google Scholar
• Abbott KC, Swanson SJ, Richter ER et al. Late urinary tract infection after renal transplantation in the United States. Am. J. Kidney Dis.44(2), 353–362 (2004).
   PubMed Web of Science ®Google Scholar
• Tveit DJ, Hypolite IO, Poropatich RK et al. Hospitalizations for bacterial pneumonia after renal transplantation in the United States. J. Nephrol.15(3), 255–262 (2002).
   PubMed Web of Science ®Google Scholar
• Xia D, Yan LN, Xu L et al. Postoperative severe pneumonia in adult liver transplant recipients. Transplant. Proc.38(9), 2974–2978 (2006).
   PubMed Web of Science ®Google Scholar
• Garbino J, Romand JA, Pittet D et al. Infection and rejection in liver transplant patients: a 10-year Swiss single-centre experience. Swiss Med. Wkly135(39–40), 587–593 (2005).
   PubMed Web of Science ®Google Scholar
• Berger N, Guggenbichler S, Steurer W et al. Bloodstream infection following 217 consecutive systemic-enteric drained pancreas transplants. BMC Infect. Dis.6, 127 (2006).
   PubMedGoogle Scholar
• Abbott KC, Oliver JD 3rd, Hypolite I et al. Hospitalizations for bacterial septicemia after renal transplantation in the United States. Am. J. Nephrol.21(2), 120–127 (2001).
   PubMed Web of Science ®Google Scholar
• Winters GL, Costanzo-Nordin MR, O’Sullivan EJ et al. Predictors of late acute orthotopic heart transplant rejection. Circulation80(5 Pt 2), III106–III110 (1989).
   PubMedGoogle Scholar
• Kirk AD. Induction immunosuppression. Transplantation82(5), 593–602 (2006).
   PubMed Web of Science ®Google Scholar
• Fishman JA, Emery V, Freeman R et al. Cytomegalovirus in transplantation – challenging the status quo. Clin. Transplant.21(2), 149–158 (2007).
   PubMed Web of Science ®Google Scholar
• Adams AB, Pearson TC, Larsen CP. Heterologous immunity: an overlooked barrier to tolerance. Immunol. Rev.196, 147–160 (2003).
   PubMed Web of Science ®Google Scholar
• Brehm MA, Markees TG, Daniels KA et al. Direct visualization of cross-reactive effector and memory allo-specific CD8 T cells generated in response to viral infections. J. Immunol.170(8), 4077–4086 (2003).
   PubMed Web of Science ®Google Scholar
• Welsh RM, Markees TG, Woda BA et al. Virus-induced abrogation of transplantation tolerance induced by donor-specific transfusion and anti-CD154 antibody. J. Virol.74(5), 2210–2218 (2000).
   PubMed Web of Science ®Google Scholar
• Janeway CA Jr. The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol Today,13(1), 11–16 (1992).
   PubMedGoogle Scholar
• Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu. Rev. Immunol.20, 197–216 (2002).
   PubMed Web of Science ®Google Scholar
• Janeway CA Jr, Medzhitov R. Introduction: the role of innate immunity in the adaptive immune response. Semin. Immunol.10(5), 349–350 (1998).
   PubMed Web of Science ®Google Scholar
• Matzinger P. The danger model: a renewed sense of self. Science296(5566), 301–305 (2002).
   PubMed Web of Science ®Google Scholar
• Asea A, Kraeft SK, Kurt-Jones EA et al. HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. Nat. Med.6(4), 435–442 (2000).
   PubMed Web of Science ®Google Scholar
• Guillot L, Balloy V, McCormack FX et al. Cutting edge: the immunostimulatory activity of the lung surfactant protein-A involves Toll-like receptor 4. J. Immunol.168(12), 5989–5992 (2002).
   PubMed Web of Science ®Google Scholar
• Johnson GB, Brunn GJ, Kodaira Y, Platt JL. Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4. J. Immunol.168(10), 5233–5239 (2002).
   PubMed Web of Science ®Google Scholar
• Leadbetter EA, Rifkin IR, Hohlbaum AM et al. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature416(6881), 603–607 (2002).
   PubMed Web of Science ®Google Scholar
• Mollen KP, Anand RJ, Tsung A et al. Emerging paradigm: Toll-like receptor 4-sentinel for the detection of tissue damage. Shock26(5), 430–437 (2006).
   PubMed Web of Science ®Google Scholar
• Ohashi K, Burkart V, Flohe S, Kolb H. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the Toll-like receptor-4 complex. J. Immunol.164(2), 558–561 (2000).
   PubMed Web of Science ®Google Scholar
• Rock KL, Hearn A, Chen CJ, Shi Y. Natural endogenous adjuvants. Springer Semin. Immunopathol.26(3), 231–246 (2005).
   PubMed Web of Science ®Google Scholar
• Termeer C, Benedix F, Sleeman J et al. Oligosaccharides of hyaluronan activate dendritic cells via Toll-like receptor 4. J. Exp. Med.195(1), 99–111 (2002).
   PubMed Web of Science ®Google Scholar
• Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell124(4), 783–801 (2006).
   PubMed Web of Science ®Google Scholar
• Kabelitz D, Medzhitov R. Innate immunity – cross-talk with adaptive immunity through pattern recognition receptors and cytokines. Curr. Opin. Immunol.19(1), 1–3 (2007).
   PubMed Web of Science ®Google Scholar
• Christopher K, Mueller TF, Ma C, Liang Y, Perkins DL. Analysis of the innate and adaptive phases of allograft rejection by cluster analysis of transcriptional profiles. J. Immunol.169(1), 522–530 (2002).
   PubMed Web of Science ®Google Scholar
• He H, Stone JR, Perkins DL. Analysis of robust innate immune response after transplantation in the absence of adaptive immunity. Transplantation73(6), 853–861 (2002).
   PubMed Web of Science ®Google Scholar
• He H, Stone JR, Perkins DL. Analysis of differential immune responses induced by innate and adaptive immunity following transplantation. Immunology109(2), 185–196 (2003).
   PubMed Web of Science ®Google Scholar
• Kawai T, Akira S. Pathogen recognition with Toll-like receptors. Curr. Opin. Immunol.17(4), 338–344 (2005).
   PubMed Web of Science ®Google Scholar
• Martinon F, Tschopp J. NLRs join TLRs as innate sensors of pathogens. Trends Immunol.26(8), 447–454 (2005).
   PubMed Web of Science ®Google Scholar
• Meylan E, Tschopp J, Karin M. Intracellular pattern recognition receptors in the host response. Nature442(7098), 39–44 (2006).
   PubMed Web of Science ®Google Scholar
• O’Riordan M, Yi CH, Gonzales R, Lee KD, Portnoy DA. Innate recognition of bacteria by a macrophage cytosolic surveillance pathway. Proc. Natl Acad. Sci. USA99(21), 13861–13866 (2002).
   PubMed Web of Science ®Google Scholar
• Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat. Immunol.5(10), 987–995 (2004).
   PubMed Web of Science ®Google Scholar
• Kawai T, Akira S. TLR signaling. Cell Death Differ.13(5), 816–825 (2006).
   PubMed Web of Science ®Google Scholar
• Schnare M, Barton GM, Holt AC et al. Toll-like receptors control activation of adaptive immune responses. Nat. Immunol.2(10), 947–950 (2001).
   PubMed Web of Science ®Google Scholar
• Gelman AE, LaRosa DF, Zhang J et al. The adaptor molecule MyD88 activates PI-3 kinase signaling in CD4+ T cells and enables CpG oligodeoxynucleotide-mediated costimulation. Immunity25(5), 783–793 (2006).
   PubMed Web of Science ®Google Scholar
• Gelman AE, Zhang J, Choi Y, Turka LA. Toll-like receptor ligands directly promote activated CD4+ T cell survival. J. Immunol.172(10), 6065–6073 (2004).
   PubMed Web of Science ®Google Scholar
• Kabelitz D. Expression and function of Toll-like receptors in T lymphocytes. Curr. Opin. Immunol.19(1), 39–45 (2007).
   PubMed Web of Science ®Google Scholar
• Goldstein DR, Tesar BM, Akira S, Lakkis FG. Critical role of the Toll-like receptor signal adaptor protein MyD88 in acute allograft rejection. J. Clin. Invest.111(10), 1571–1578 (2003).
   PubMed Web of Science ®Google Scholar
• Goldstein D. Role of MyD88 and Trif in acute allograft rejection: glass half full or empty? Eur. J. Immunol.36(10), 2820 (2006).
   PubMed Web of Science ®Google Scholar
• Tesar BM, Zhang J, Li Q, Goldstein DR. Th1 immune responses to fully MHC mismatched allografts are diminished in the absence of MyD88, a Toll-like receptor signal adaptor protein. Am. J. Transplant.4(9), 1429–1439 (2004).
   PubMed Web of Science ®Google Scholar
• Walker WE, Nasr IW, Camirand G et al. Absence of innate MyD88 signaling promotes inducible allograft acceptance. J. Immunol.177(8), 5307–5316 (2006).
   PubMed Web of Science ®Google Scholar
• Chen L, Wang T, Zhou P et al. TLR engagement prevents transplantation tolerance. Am. J. Transplant.6(10), 2282–2291 (2006).
   PubMed Web of Science ®Google Scholar
• Thornley TB, Brehm MA, Markees TG et al. TLR agonists abrogate costimulation blockade-induced prolongation of skin allografts. J. Immunol.176(3), 1561–1570 (2006).
   PubMed Web of Science ®Google Scholar
• Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science299(5609), 1033–1036 (2003).
   PubMed Web of Science ®Google Scholar
• Yang Y, Huang CT, Huang X, Pardoll DM. Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat. Immunol.5(5), 508–515 (2004).
   PubMed Web of Science ®Google Scholar
• Stetson DB, Medzhitov R. Type I interferons in host defense. Immunity25(3), 373–381 (2006).
   PubMed Web of Science ®Google Scholar
• Arbour NC, Lorenz E, Schutte BC et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat. Genet.25(2), 187–191 (2000).
   PubMed Web of Science ®Google Scholar
• Palmer SM, Burch LH, Davis RD et al. The role of innate immunity in acute allograft rejection after lung transplantation. Am. J. Respir. Crit. Care Med.168(6), 628–632 (2003).
   PubMed Web of Science ®Google Scholar
• Palmer SM, Burch LH, Trindade AJ et al. Innate immunity influences long-term outcomes after human lung transplant. Am. J. Respir. Crit. Care Med.171(7), 780–785 (2005).
   PubMed Web of Science ®Google Scholar
• Palmer SM, Klimecki W, Yu L et al. Genetic regulation of rejection and survival following human lung transplantation by the innate immune receptor CD14. Am. J. Transplant.7(3), 693–699 (2007).
   PubMed Web of Science ®Google Scholar
• Ducloux D, Deschamps M, Yannaraki M et al. Relevance of Toll-like receptor-4 polymorphisms in renal transplantation. Kidney Int.67(6), 2454–2461 (2005).
   PubMed Web of Science ®Google Scholar
• Nogueira E, Ozaki KS, Macusso GD et al. Incidence of donor and recipient Toll-like receptor-4 polymorphisms in kidney transplantation. Transplant. Proc.39(2), 412–414 (2007).
   PubMed Web of Science ®Google Scholar
• Palmer SM, Burch LH, Mir S et al. Donor polymorphisms in Toll-like receptor-4 influence the development of rejection after renal transplantation. Clin. Transplant.20(1), 30–36 (2006).
   PubMedGoogle Scholar
• Methe H, Zimmer E, Grimm C, Nabauer M, Koglin J. Evidence for a role of Toll-like receptor 4 in development of chronic allograft rejection after cardiac transplantation. Transplantation78(9), 1324–1331 (2004).
   PubMed Web of Science ®Google Scholar
• Andrejeva J, Childs KS, Young DF et al. The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, MDA-5, and inhibit its activation of the IFN-b promoter. Proc. Natl Acad. Sci. USA101(49), 17264–17269 (2004).
   PubMed Web of Science ®Google Scholar
• Inohara N, Chamaillard M, McDonald C, Nunez G. NOD-LRR proteins: role in host–microbial interactions and inflammatory disease. Annu. Rev. Biochem.74, 355–383 (2005).
   PubMed Web of Science ®Google Scholar
• Kang DC, Gopalkrishnan RV, Wu Q et al. MDA-5: an interferon-inducible putative RNA helicase with double-stranded RNA-dependent ATPase activity and melanoma growth-suppressive properties. Proc. Natl Acad. Sci. USA99(2), 637–642 (2002).
   PubMed Web of Science ®Google Scholar
• Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature440(7081), 237–241 (2006).
   PubMed Web of Science ®Google Scholar
• Yoneyama M, Kikuchi M, Matsumoto K et al. Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. J. Immunol.175(5), 2851–2858 (2005).
   PubMed Web of Science ®Google Scholar
• Yoneyama M, Kikuchi M, Natsukawa T et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat. Immunol.5(7), 730–737 (2004).
   PubMed Web of Science ®Google Scholar
• Mariathasan S, Weiss DS, Newton K et al. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature440(7081), 228–232 (2006).
   PubMed Web of Science ®Google Scholar
• Agostini L, Martinon F, Burns K et al. NALP3 forms an IL-1b-processing inflammasome with increased activity in Muckle–Wells autoinflammatory disorder. Immunity20(3), 319–325 (2004).
   PubMed Web of Science ®Google Scholar
• Mariathasan S, Newton K, Monack DM et al. Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature430(6996), 213–218 (2004).
   PubMed Web of Science ®Google Scholar
• Chamaillard M, Girardin SE, Viala J, Philpott DJ. Nods, Nalps and Naip: intracellular regulators of bacterial-induced inflammation. Cell. Microbiol.5(9), 581–592 (2003).
   PubMed Web of Science ®Google Scholar
• Chamaillard M, Hashimoto M, Horie Y et al. An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid. Nat. Immunol.4(7), 702–707 (2003).
   PubMed Web of Science ®Google Scholar
• Girardin SE, Boneca IG, Viala J et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J. Biol. Chem.278(11), 8869–8872 (2003).
   PubMed Web of Science ®Google Scholar
• Kruger B, Boger CA, Schroppel B et al. Impact of NOD2/CARD15 haplotypes on the outcome after kidney transplantation. Transpl. Int.20(7), 600–607 (2007).
   PubMed Web of Science ®Google Scholar
• Stetson DB, Medzhitov R. Recognition of cytosolic DNA activates an IRF3-dependent innate immune response. Immunity24(1), 93–103 (2006).
   PubMed Web of Science ®Google Scholar
• Ishii KJ, Coban C, Kato H et al. A Toll-like receptor-independent antiviral response induced by double-stranded B-form DNA. Nat. Immunol.7(1), 40–48 (2006).
   PubMed Web of Science ®Google Scholar
• Bogdan C, Mattner J, Schleicher U. The role of type I interferons in non-viral infections. Immunol. Rev.202, 33–48 (2004).
   PubMed Web of Science ®Google Scholar
• Decker T, Muller M, Stockinger S. The yin and yang of type I interferon activity in bacterial infection. Nat. Rev. Immunol.5(9), 675–687 (2005).
   PubMed Web of Science ®Google Scholar
• Mancuso G, Midiri A, Biondo C et al. Type I IFN signaling is crucial for host resistance against different species of pathogenic bacteria. J. Immunol.178(5), 3126–3133 (2007).
   PubMed Web of Science ®Google Scholar
• Perry AK, Chen G, Zheng D, Tang H, Cheng G. The host type I interferon response to viral and bacterial infections. Cell Res.15(6), 407–422 (2005).
   PubMed Web of Science ®Google Scholar
• Stetson DB, Medzhitov R. Antiviral defense: interferons and beyond. J. Exp. Med.203(8), 1837–1841 (2006).
   PubMed Web of Science ®Google Scholar
• Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu. Rev. Biochem.67, 227–264 (1998).
   PubMed Web of Science ®Google Scholar
• van Boxel-Dezaire AH, Rani MR, Stark GR. Complex modulation of cell type-specific signaling in response to type I interferons. Immunity25(3), 361–372 (2006).
   PubMed Web of Science ®Google Scholar
• Le Bon A, Etchart N, Rossmann C et al. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat. Immunol.4(10), 1009–1015 (2003).
   PubMed Web of Science ®Google Scholar
• Kolumam GA, Thomas S, Thompson LJ, Sprent J, Murali-Krishna K. Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J. Exp. Med.202(5), 637–650 (2005).
   PubMed Web of Science ®Google Scholar
• Nguyen KB, Watford WT, Salomon R et al. Critical role for STAT4 activation by type 1 interferons in the interferon-g response to viral infection. Science297(5589), 2063–2066 (2002).
   PubMed Web of Science ®Google Scholar
• Nguyen KB, Salazar-Mather TP, Dalod MY et al. Coordinated and distinct roles for IFN-a b, IL-12, and IL-15 regulation of NK cell responses to viral infection. J. Immunol.169(8), 4279–4287 (2002).
   PubMed Web of Science ®Google Scholar
• Zhang X, Sun S, Hwang I, Tough DF, Sprent J. Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. Immunity8(5), 591–599 (1998).
   PubMed Web of Science ®Google Scholar
• Baid S, Tolkoff-Rubin N, Saidman S et al. Acute humoral rejection in hepatitis C-infected renal transplant recipients receiving antiviral therapy. Am. J. Transplant.3(1), 74–78 (2003).
   PubMed Web of Science ®Google Scholar
• Tovey MG, Benizri E, Gugenheim J et al. Role of the type I interferons in allograft rejection. J. Leukoc. Biol.59(4), 512–517 (1996).
   PubMed Web of Science ®Google Scholar
• Walter T, Dumortier J, Guillaud O et al. Rejection under a interferon therapy in liver transplant recipients. Am. J. Transplant.7(1), 177–184 (2007).
   PubMedGoogle Scholar
• Carbognin SJ, Solomon NM, Yeo FE et al. Acute renal allograft rejection following pegylated IFN-α treatment for chronic HCV in a repeat allograft recipient on hemodialysis: a case report. Am. J. Transplant.6(7), 1746–1751 (2006).
   PubMed Web of Science ®Google Scholar
• Gugenheim J, Tovey M, Gigou M et al. Prolongation of heart allograft survival in rats by interferon-specific antibodies and low dose cyclosporin A. Transpl. Int.5(Suppl. 1), S460–S461 (1992).
   PubMed Web of Science ®Google Scholar
• Afifi MS, Kumar V, Bennett M. Stimulation of genetic resistance to marrow grafts in mice by interferon-α/β. J. Immunol.134(6), 3739–3745 (1985).
   PubMed Web of Science ®Google Scholar
• Thornley TB, Phillips NE, Beaudette-Zlatanova BC et al. Type 1 IFN mediates cross-talk between innate and adaptive immunity that abrogates transplantation tolerance. J. Immunol.179(10), 6620–6629 (2007).
   PubMed Web of Science ®Google Scholar
• Zhang D, Zhang G, Hayden MS et al. A Toll-like receptor that prevents infection by uropathogenic bacteria. Science303(5663), 1522–1526 (2004).
   PubMed Web of Science ®Google Scholar